Đang chuẩn bị nút TẢI XUỐNG, xin hãy chờ
Tải xuống
Genetics-based basket trials have emerged to test targeted therapeutics across multiple cancer types. However, while vemurafenib is FDA-approved for BRAF-V600E melanomas, the non-melanoma basket trial was unsuccessful, suggesting mutation status is insufficient to predict response. | Tumor cell sensitivity to vemurafenib can be predicted from protein expression in a BRAF-V600E basket trial setting